{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:51:31Z","timestamp":1793893891411,"version":"4.8.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Primary central nervous system post-transplant lymphoproliferative disorder (PCNS-PTLD) is a rare condition, posing diagnostic and treatment challenges, with histological biopsy essential for diagnosis. Standardized treatment protocols are lacking. This disease requires urgent attention due to the increasing number of organ transplant surgeries and the use of immunosuppressive agents.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From 2020 to 2023, our center diagnosed five patients with PCNS-PTLD. We reviewed their clinical records and conducted a comprehensive analysis of 22 literatures on PCNS-PTLD cases following renal transplantation or allogeneic hematopoietic stem cell transplantation (HSCT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Four patients had previously received a kidney transplant, one had undergone allogeneic HSCT. The median time from the last transplant surgery to the diagnosis of PCNS-PTLD differs between kidney transplant (21.5 years) and allogeneic HSCT (9 months). Common symptoms included motor weakness (<jats:italic>n<\/jats:italic> = 4), headache (<jats:italic>n<\/jats:italic> = 2), confusion (<jats:italic>n<\/jats:italic> = 2), and nausea (<jats:italic>n<\/jats:italic> = 2), with ring-enhancing (<jats:italic>n<\/jats:italic> = 5), typically solitary (<jats:italic>n<\/jats:italic> = 3) and supratentorial (<jats:italic>n<\/jats:italic> = 3) lesions on imaging. Diagnosis involved robot-assisted stereotactic brain biopsy (<jats:italic>n<\/jats:italic> = 4) or craniotomy (<jats:italic>n<\/jats:italic> = 1), all showing Epstein-Barr virus and CD20 positivity. Most cases (<jats:italic>n<\/jats:italic> = 4) were monomorphic diffuse large B-cell lymphoma. Treatment included rituximab (<jats:italic>n<\/jats:italic> = 3), surgical resection (<jats:italic>n<\/jats:italic> = 2), zanubrutinib (<jats:italic>n<\/jats:italic> = 1), whole-brain radiation (<jats:italic>n<\/jats:italic> = 1), and methotrexate (<jats:italic>n<\/jats:italic> = 1). At the last follow-up, the median duration of follow-up for all patients was 19 months. During this time, 3 patients had died and 2 patients were still alive.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In patients with a history of kidney transplantation or allogeneic HSCT who are on long-term immunosuppressive therapy, any neurological symptoms, particularly the presence of supratentorial ring-enhancing masses in the brain on imaging, whether solitary or multiple, should raise high suspicion for this disease, warranting a timely brain biopsy. Additionally, we found that besides reducing immunosuppressants, zanubrutinib may be a potential, safe, and effective treatment for this condition. Moreover, post-surgical administration of rituximab in conjunction with whole-brain radiotherapy also appears to be a potentially safe and effective approach.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1392691","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T05:08:21Z","timestamp":1715749701000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["A disease warranting attention from neurosurgeons: primary central nervous system post-transplant lymphoproliferative disorder"],"prefix":"10.3389","volume":"15","author":[{"given":"Lei","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinkun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penghu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhi","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoguang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1200\/EDBK_159030","article-title":"Current management concepts: primary central nervous system lymphoma, natural killer T-cell lymphoma nasal type, and post-transplant lymphoproliferative disorder","volume":"36","author":"Batchelor","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"B2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.5114\/fn.2017.70487","article-title":"EBV-positive post-transplant lymphoproliferative disorder presenting as primary diffuse large B-cell lymphoma of the central nervous system","volume":"55","author":"Xu","year":"2017","journal-title":"Folia Neuropathologica"},{"key":"B3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/MD.0000000000021844","article-title":"Primary central nervous system lymphoma after heart transplantation: a case report and literature review","volume":"99","author":"Zhu","year":"2020","journal-title":"Medicine"},{"key":"B4","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1227\/NEU.0b013e31828cf619","article-title":"A case series of primary central nervous system posttransplantation lymphoproliferative disorder: imaging and clinical characteristics","volume":"72","author":"Lake","year":"2013","journal-title":"Neurosurgery"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e13302","DOI":"10.1111\/petr.13302","article-title":"Successful nivolumab therapy in an allogeneic stem cell transplant child with post-transplant lymphoproliferative disorder","volume":"22","author":"Kassa","year":"2018","journal-title":"Pediat Transplantat"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1007\/s00277-021-04548-2","article-title":"Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry","volume":"100","author":"Zimmermann","year":"2021","journal-title":"Ann Hematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40620-013-0026-z","article-title":"Primary brain lymphomas after kidney transplantation: an under-recognized problem?","volume":"27","author":"Sola-Valls","year":"2014","journal-title":"J Nephrol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s13365-018-0711-8","article-title":"Post-transplant primary central nervous system lymphoma after Epstein-Barr virus cerebellitis","volume":"25","author":"Valencia-Sanchez","year":"2019","journal-title":"J Neurovirol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.transproceed.2023.03.048","article-title":"Outcome of brain lymphoma in a high epstein-barr virus-prevalence country after kidney transplantation","volume":"55","author":"Huang","year":"2023","journal-title":"Transplant Proc"},{"key":"B10","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/1744-9987.12568","article-title":"Primary central nervous system post-transplant lymphoproliferative disorder following kidney transplantation: a multi-institution study in Japan over 30 years","volume":"21","year":"2017","journal-title":"Ther Apher Dial"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1111\/ajt.16628","article-title":"Successful treatment of Epstein-Barr virus-associated primary central nervous system lymphoma due to post-transplantation lymphoproliferative disorder, with ibrutinib and third-party Epstein-Barr virus-specific T cells","volume":"21","author":"Law","year":"2021","journal-title":"Am J Transplantat"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1111\/nep.13254","article-title":"High-dose intravenous methotrexate with high-flux, extended-hours haemodialysis in treatment of primary central nervous system, post-transplant lymphoproliferative disorder and end-stage kidney disease: a case report","volume":"23","author":"Yeung","year":"2018","journal-title":"Nephrology"},{"key":"B13","unstructured":"Pediatric central nervous system posttransplant lymphoproliferative disorder16957\n            BrennanKC\n            LoweLH\n            YeaneyGA\n          Am J Neuroradiol262005"},{"key":"B14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.12809\/hkmj134095","article-title":"Post-transplantation primary central nervous system lymphoma in a patient with systemic lupus erythematosus and prolonged use of immunosuppressant","volume":"20","author":"Teresa","year":"2014","journal-title":"Hong Kong Med J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.2169\/internalmedicine.9613-17","article-title":"Primary central nervous system post-transplant lymphoproliferative disorder diagnosed by peripheral facial nerve palsy","volume":"57","author":"Imafuku","year":"2018","journal-title":"Intern Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1590\/0004-282x20180049","article-title":"Primary central nervous system post-transplant lymphoproliferative disorder mimicking toxoplasmosis","volume":"76","author":"Reis","year":"2018","journal-title":"Arq Neuropsiquiatr"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.21873\/anticanres.15893","article-title":"Primary central nervous system post-transplant lymphoproliferative disorder misdiagnosed as glioblastoma: a case report","volume":"42","author":"Tanaka","year":"2022","journal-title":"Anticancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jocn.2019.08.053","article-title":"Solitary intraventricular Hodgkin lymphoma post-transplant lymphoproliferative disease (HL-PTLD): case report","volume":"69","author":"Azriel","year":"2019","journal-title":"J Clini Neurosci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s00467-013-2499-3","article-title":"Successful treatment of central nervous system PTLD with rituximab and cranial radiotherapy","volume":"28","author":"Said-Conti","year":"2013","journal-title":"Pediat Nephrol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"E102","DOI":"10.1111\/j.1399-3062.2012.00781.x","article-title":"Successful treatment of monomorphic primary central nervous system post-transplantation lymphoproliferative disorder 5 years after kidney transplantation","volume":"14","author":"Yaginuma","year":"2012","journal-title":"Transplant Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1399-3062.2011.00621.x","article-title":"Isolated cerebral manifestation of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case of clinical and diagnostic challenges","volume":"13","author":"Kittan","year":"2011","journal-title":"Transplant Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/j.1399-3062.2009.00409.x","article-title":"Primary central nervous system post-transplant lymphoproliferative disorder presenting as cerebral hemorrhage after unrelated bone marrow transplantation","volume":"11","author":"Aisa","year":"2009","journal-title":"Transplant Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.31547\/bct-2018-004","article-title":"Primary CNS post-transplant lymphoproliferative disorder following haploidentical HSCT using post-transplant high-dose cyclophosphamide","volume":"2","author":"Toyosaki","year":"2019","journal-title":"Blood Cell Therapy"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1016\/j.transproceed.2020.08.002","article-title":"Toxoplasmic encephalitis followed by primary EBV-associated post-transplant lymphoproliferative disorder of the central nervous system in a patient undergoing allogeneic hematopoietic stem cell transplant: a case report","volume":"52","author":"Mayumi","year":"2020","journal-title":"Transplant Proc"},{"key":"B25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.lrr.2019.04.003","article-title":"Central nervous system post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: the Nagasaki transplant group experience","volume":"11","author":"Sakamoto","year":"2019","journal-title":"Leukemia Res Reports"},{"key":"B26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11899-013-0162-5","article-title":"Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies","volume":"8","author":"Al-Mansour","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"B27","unstructured":"Posttransplant Lymphoproliferative Disorders2023"},{"key":"B28","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/cncr.24834","article-title":"Primary central nervous system post-transplantation lymphoproliferative disorder: an international primary central nervous system lymphoma collaborative group report","volume":"116","author":"Cavaliere","year":"2010","journal-title":"Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1159\/000347225","article-title":"Posttransplant lymphoproliferative disorder of the central nervous system","volume":"80","author":"Kempf","year":"2013","journal-title":"Pathobiology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/JVI.00238-19","article-title":"Mechanisms of B-cell oncogenesis induced by Epstein-Barr virus","volume":"93","author":"Saha","year":"2019","journal-title":"J Virol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/HS9.0000000000000640","article-title":"Clinicopathologic characteristics, treatment, and outcomes of post-transplant lymphoproliferative disorders: a single-institution experience using 2017 WHO diagnostic criteria","volume":"5","author":"King","year":"2021","journal-title":"Hemasphere"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/j.1600-6143.2008.02183.x","article-title":"EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial","volume":"8","author":"Tsai","year":"2008","journal-title":"Am J Transplantat"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13244-019-0726-6","article-title":"Primary central nervous system post-transplant lymphoproliferative disorders: the spectrum of imaging appearances and differential","volume":"10","author":"White","year":"2019","journal-title":"Insights Imaging"},{"key":"B34","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/tid.12090","article-title":"E pstein-B arr virus (EBV) load in cerebrospinal fluid and peripheral blood of patients with EBV-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Liu","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/sj.bmt.1705575","article-title":"Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein-Barr virus DNA PCR","volume":"39","author":"Hamadani","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"B36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00234-005-0024-5","article-title":"Pattern of T2 hypointensity associated with ring-enhancing brain lesions can help to differentiate pathology","volume":"48","author":"Schwartz","year":"2006","journal-title":"Neuroradiology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/tid.12431","article-title":"Epstein-Barr virus encephalitis in a renal transplant recipient manifesting as hemorrhagic, ring-enhancing mass lesions","volume":"17","author":"Babik","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.3171\/2017.2.FOCUS16579","article-title":"Robot-assisted procedures in pediatric neurosurgery","volume":"42","author":"De Benedictis","year":"2017","journal-title":"Neurosurg Focus"},{"key":"B39","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3171\/2020.7.PEDS20373","article-title":"Robot-assisted stereotactic biopsy of pediatric brainstem and thalamic lesions","volume":"27","author":"Gupta","year":"2020","journal-title":"J Neurosurg: Pediatr"},{"key":"B40","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00701-019-03808-5","article-title":"Stereotactic brain biopsy: evaluation of robot-assisted procedure in 60 patients","volume":"161","author":"Terrier","year":"2019","journal-title":"Acta Neurochir"},{"key":"B41","doi-asserted-by":"publisher","first-page":"196","DOI":"10.25100\/cm.v47i4.1989","article-title":"Treatment of post-transplantation lymphoproliferative disorders after kidney transplant with rituximab and conversion to m-TOR inhibitor","volume":"47","author":"Nieto-Rios","year":"2016","journal-title":"Colombia M\u00e9dica"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1173776","DOI":"10.3389\/fneur.2023.1173776","article-title":"Novel application of robot-guided stereotactic technique on biopsy diagnosis of intracranial lesions","volume":"14","author":"Feng","year":"2023","journal-title":"Front Neurol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1600-6143.2010.03387.x","article-title":"Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder","volume":"11","author":"Reshef","year":"2011","journal-title":"Am J Transplantat"},{"key":"B44","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/cncr.11035","article-title":"Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation Cancer: Interdisciplinary","volume":"97","author":"Shibamoto","year":"2003","journal-title":"Int J Am Cancer Soc"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1111\/j.1600-6143.2009.02598.x","article-title":"Isolated central nervous system posttransplant lymphoproliferative disorder treated with high-dose intravenous methotrexate","volume":"9","author":"Nabors","year":"2009","journal-title":"Am J Transplantat"},{"key":"B46","first-page":"66","article-title":"High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease","volume":"2","author":"Mutsando","year":"2012","journal-title":"Am J Blood Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41408-023-00902-x","article-title":"Zanubrutinib: past, present, and future","volume":"13","author":"Tam","year":"2023","journal-title":"Blood Cancer J"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-3782984\/v1","article-title":"Efficacy of BTK inhibitor administered for central high-risk systemic diffuse large B cell lymphoma and primary central nervous system lymphoma: a single-center retrospective study","author":"Zhang","year":"2024","journal-title":"Res Square"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.hoc.2016.07.013","article-title":"The challenge of primary central nervous system lymphoma","volume":"30","author":"Carnevale","year":"2016","journal-title":"Hematol\/Oncol Clini"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/neuonc\/nos159","article-title":"Surgery for primary CNS lymphoma? Challenging a paradigm","volume":"14","author":"Weller","year":"2012","journal-title":"Neuro-oncology"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1392691\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T05:08:25Z","timestamp":1715749705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1392691\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":50,"alternative-id":["10.3389\/fneur.2024.1392691"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1392691","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,15]]},"article-number":"1392691"}}